Epredia、サンプルの追跡と研究室の効率を向上させるレーザー・カセット・プリンターを発表

Portsmouth, NH
November 1, 2024

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMateTM Laser slide printer has received an Innovative Technology designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest healthcare provider performance improvement company in the country. Epredia exhibited SlideMate Laser at the Vizient Innovative Technology Exchange Sept. 18 in Las Vegas.

Each year, healthcare experts serving on Vizient provider-led councils review select products and technologies for their potential to enhance clinical care, patient safety, or healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and the business models of healthcare organizations.
Epredia’s SlideMate portfolio of slide printers is used in the cancer diagnostics process to identify and help track tissue samples. The company designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability. SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow. This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, improving both patient sample tracking and efficiency. 

SlideMate Laser also enhances laboratory efficiency by optimizing the slide movements through the printer and reducing potential downtime compared to thermal transfer and ink jet printers. Without the need to purchase, ink, bulbs or tape for slide printers, users can expect lower operational costs. With both on-demand and batch printing options, SlideMate Laser can integrate into a range of workflows. The laser printer’s software is easy to use and can be directly interfaced to a Laboratory Information System.

SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. Epredia also offers the specialized slides designed for use with SlideMate Laser to help laboratories make a smooth transition to precision laser printing.

Steven Lynum, President of Epredia, said, “We set out to transform the anatomical pathology market with precision cancer diagnostics solutions. The Vizient Innovative Technology Designation is a true honor, and further proof that SlideMate Laser contributes to our goal of providing a seamless end-to-end laboratory workflow. Our team remains focused on improving patient outcomes by enabling pathologists to do their best work.”

“Congratulations to Epredia for achieving this peer-designated status,” said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader. “Our customer council deemed the SlideMate Laser worthy of this designation for its potential to make a real difference in the healthcare industry.”

Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. 

---

Eprediaについて

Eprediaについて

Eprediaは解剖学的病理学分野におけるグローバルリーダーであり、精密がん診断と組織診断のための包括的なソリューションを提供しています。Erie Scientific、Menzel-Gläser、Microm、Shandon、Richard-Allan Scientificなどの主要ブランドを擁し、顕微鏡スライド、器具、消耗品などのポートフォリオを提供しています。Eprediaは2019年にPHC HoldingsによるThermo Fisher Scientific’のAnatomical Pathology事業の買収を受けて設立された。Eprediaは米国、英国、ドイツ、スイス、中国の主要拠点で事業を展開しており、総従業員数は約1,200人である。Eprediaは、世界中の患者のためにがん診断を強化することにより、生命を向上させるという使命の達成に全力を尽くしています。Eprediaとその製品に関する詳しい情報は、www.epredia.com.

をご覧ください。

PHCホールディングス株式会社について（PHCグループ）

PHCホールディングス株式会社（東証6523）は、人々の生活に良い影響を与え、改善するヘルスケアソリューションを通じて、社会の健康に貢献することを使命とするグローバルヘルスケア企業です。その子会社（PHCグループと総称）には、PHCコーポレーション、Epredia、Ascensia Diabetes Care、LSI Medience Corporation、Mediford、Wemexがある。これらの企業は、糖尿病管理、ヘルスケアソリューション、ライフサイエンス、診断に関わるソリューションの開発、製造、販売、サービスを行っている。PHC Group’の2022年度の連結売上高は3,564億円で、125カ国以上で製品とサービスをグローバルに販売しています。
www.phchd.com

PHCグループ’の2022年度の連結売上高は3,564億円で、125カ国以上で製品とサービスをグローバルに販売しています。

詳細については、以下までお問い合わせください。

Julia Cottrill
PHCグループ・コーポレート・コミュニケーション
Email：julia.cottrill@phchd.com